

Sunil V Badve

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8267617/publications.pdf>

Version: 2024-02-01

124
papers

4,517
citations

101496

36
h-index

123376

61
g-index

127
all docs

127
docs citations

127
times ranked

5215
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. <i>Journal of Vascular Access</i> , 2024, 25, 193-202.	0.5	2
2	Relationship Between Dietary Phosphate Intake and Biomarkers of Bone and Mineral Metabolism in Australian Adults With Chronic Kidney Disease. , 2022, 32, 58-67.		4
3	Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 59-76.	3.0	16
4	Representativeness of the PDOPPS cohort compared to the Australian PD population. <i>Peritoneal Dialysis International</i> , 2022, 42, 403-414.	1.1	2
5	Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease. , 2022, 1, .		17
6	Sex differences in chronic kidney disease prevalence in Asia: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1144-1151.	1.4	5
7	Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis. <i>Journal of Nephrology</i> , 2022, 35, 1159-1170.	0.9	8
8	Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysisâ€”International Results from PDOPPS. <i>Kidney International Reports</i> , 2021, 6, 313-324.	0.4	29
9	The effects of dipeptidyl peptidaseâ€4 inhibitors on kidney outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 763-773.	2.2	12
10	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 372, m4573.	3.0	322
11	Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the <scp>ADVANCE</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1420-1425.	2.2	3
12	Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 346-352.	1.0	6
13	A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes. <i>Kidney International Reports</i> , 2021, 6, 695-705.	0.4	21
14	Dietary Phosphate Consumption in Australians With Stages 3b and 4 Chronic Kidney Disease. , 2021, 31, 155-163.		2
15	Recent evidence on the effect of treatment of metabolic acid on the progression of kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 467-473.	1.0	3
16	Editor's note. <i>Internal Medicine Journal</i> , 2021, 51, 1368-1368.	0.5	0
17	The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1470-1479.	2.2	11
18	Treatment preferences for primary membranous nephropathy: Results of a multinational survey among nephrologists in the South Asia Pacific region. <i>Nephrology</i> , 2021, , .	0.7	0

#	ARTICLE	IF	CITATIONS
19	Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1576-1586.	2.2	33
20	Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease. <i>Nutrients</i> , 2020, 12, 3376.	1.7	1
21	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2653-2666.	3.0	52
22	Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal Recovery. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812092262.	0.6	6
23	Effects of Allopurinol on the Progression of Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 2504-2513.	13.9	281
24	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2020, 40, 47-56.	1.1	24
25	Icodextrin use for peritoneal dialysis in Australia: A cohort study using Australia and New Zealand Dialysis and Transplant Registry. <i>Peritoneal Dialysis International</i> , 2020, 40, 209-219.	1.1	4
26	Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2020, 51, 201-215.	1.4	24
27	Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. <i>American Journal of Kidney Diseases</i> , 2020, 76, 311-320.	2.1	16
28	Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 909-910.	3.0	1
29	Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in REnal Disease (FAVOURED) trial. <i>PLoS ONE</i> , 2019, 14, e0213274.	1.1	8
30	Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. <i>BMJ Open</i> , 2019, 9, e024382.	0.8	18
31	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 181.	2.0	108
32	Recent evidence for direct oral anticoagulants in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 251-261.	1.0	4
33	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. <i>Lancet Rheumatology</i> , The, 2019, 1, e220-e228.	2.2	38
34	Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1035-1044.	0.4	12
35	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2018, 38, 257-265.	1.1	12
36	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 188-197.	2.1	85

#	ARTICLE	IF	CITATIONS
37	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. American Journal of Kidney Diseases, 2018, 71, 814-821.	2.1	66
38	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 2018, 9, CD011798.	1.5	48
39	Biocompatible dialysis fluids for peritoneal dialysis. The Cochrane Library, 2018, 2018, CD007554.	1.5	46
40	Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?. American Journal of Kidney Diseases, 2018, 72, 776-778.	2.1	9
41	The Relationship between Body Mass Index and Organism-Specific Peritonitis. Peritoneal Dialysis International, 2018, 38, 206-214.	1.1	9
42	Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open, 2018, 8, e018794.	0.8	60
43	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology, 2017, 22, 823-824.	0.7	3
44	Association between serum hepcidin and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology, 2017, 22, 548-554.	0.7	11
45	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2017, 2, CD009966.	1.5	20
46	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2017, 37, 397-406.	1.1	14
47	Breast Cancer and Transplantation. American Journal of Transplantation, 2017, 17, 2243-2253.	2.6	21
48	Representativeness of Honeypot Trial Participants to Australasian PD Patients. Peritoneal Dialysis International, 2017, 37, 516-522.	1.1	3
49	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. JAMA Internal Medicine, 2017, 177, 184.	2.6	77
50	EARLY PERITONITIS AND ITS OUTCOME IN INCIDENT PERITONEAL DIALYSIS PATIENTS. Peritoneal Dialysis International, 2017, , pdi.2017.00029.	1.1	11
51	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2017, 37, 619-626.	1.1	18
52	Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1090-1099.	2.2	94
53	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. Kidney and Blood Pressure Research, 2017, 42, 1033-1044.	0.9	7
54	Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer - a population cohort study. Oncotarget, 2017, 8, 77771-77782.	0.8	20

#	ARTICLE	IF	CITATIONS
55	APPETITE PREDICTS INTAKE AND NUTRITIONAL STATUS IN PATIENTS RECEIVING PERITONEAL DIALYSIS. Journal of Renal Care, 2016, 42, 123-131.	0.6	11
56	Baseline characteristics of the omega-3 fatty acids (FISH oils) and Aspirin in Vascular access OUTcomes in Renal Disease (FAVOURED) study. Nephrology, 2016, 21, 217-228.	0.7	10
57	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney International, 2016, 89, 1337-1345.	2.6	44
58	The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 554-563.	2.1	51
59	Center-Specific Factors Associated with Peritonitis Risk—A Multi-Center Registry Analysis. Peritoneal Dialysis International, 2016, 36, 509-518.	1.1	54
60	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Report, 2016, 21, 14-23.	1.4	8
61	Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1845-1855.	2.2	30
62	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2016, 316, 313.	3.8	329
63	Duration of Hemodialysis following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure. Peritoneal Dialysis International, 2016, 36, 623-630.	1.1	71
64	Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. BMJ, The, 2016, 355, i5599.	3.0	25
65	Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multicentre registry study. Nephrology, 2016, 21, 387-396.	0.7	8
66	Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrology Dialysis Transplantation, 2016, 31, 1425-1436.	0.4	34
67	The β -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 67, 902-911.	2.1	36
68	End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases. American Journal of Nephrology, 2015, 42, 177-184.	1.4	26
69	The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. Peritoneal Dialysis International, 2015, 35, 222-228.	1.1	19
70	A nephrology guide to reading and using systematic reviews of randomized trials. Nephrology Dialysis Transplantation, 2015, 30, 878-884.	0.4	2
71	Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. Canadian Journal of Kidney Health and Disease, 2015, 2, 66.	0.6	8
72	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUTcomes in Renal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology, 2015, 16, 89.	0.8	21

#	ARTICLE	IF	CITATIONS
73	Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 450-459.	1.1	16
74	The Effect of Exit-Site Antibacterial Honey versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the HoneyPot Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 712-721.	1.1	14
75	Daily Home Hemodialysis: Balancing Cardiovascular Benefits With Infectious Harms. <i>American Journal of Kidney Diseases</i> , 2015, 65, 6-8.	2.1	2
76	The rationale and design of the <i>BLOCKER</i> to lower cardiovascular events (<i>BLOCKADE</i>) feasibility study. <i>Nephrology</i> , 2015, 20, 140-147.	0.7	6
77	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 49-57.	2.1	29
78	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. <i>PLoS ONE</i> , 2014, 9, e114897.	1.1	37
79	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2277-2286.	0.4	40
80	Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. <i>Kidney International</i> , 2014, 85, 23-30.	2.6	17
81	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 406-413.	0.4	191
82	The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2014, 34, 219-226.	1.1	14
83	Haemodialysis catheter care in practice. <i>Nature Reviews Nephrology</i> , 2014, 10, 131-133.	4.1	2
84	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1940-1947.	0.4	34
85	Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 23-30.	4.6	76
86	Biocompatible dialysis fluids for peritoneal dialysis. <i>The Cochrane Library</i> , 2014, , CD007554.	1.5	85
87	The Association between Peritoneal Dialysis Modality and Peritonitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1091-1097.	2.2	49
88	Interventions for erythropoietin-resistant anaemia in dialysis patients. <i>The Cochrane Library</i> , 2013, , CD006861.	1.5	6
89	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 96-103.	2.1	48
90	The Outcomes of Patients with ESRD and ANCA-Associated Vasculitis in Australia and New Zealand. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 773-780.	2.2	43

#	ARTICLE	IF	CITATIONS
91	The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. <i>Kidney International</i> , 2013, 84, 969-979.	2.6	73
92	Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. <i>Kidney International</i> , 2013, 83, 503-510.	2.6	59
93	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1556-1563.	2.2	26
94	Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1899-1907.	0.4	75
95	The HoneyPot Randomized Controlled Trial Statistical Analysis Plan. <i>Peritoneal Dialysis International</i> , 2013, 33, 426-435.	1.1	9
96	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. <i>Peritoneal Dialysis International</i> , 2013, 33, 75-85.	1.1	17
97	End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 455-461.	0.4	37
98	Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes. <i>International Journal of Nephrology</i> , 2012, 2012, 1-9.	0.7	18
99	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1398-1405.	3.0	198
100	Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 381-387.	0.4	38
101	Weekend Compared with Weekday Presentations of Peritoneal Dialysis-associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2012, 32, 516-524.	1.1	16
102	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2028-2036.	0.4	31
103	A Randomized Controlled Trial of Intravenous or Oral Iron for Posttransplant Anemia in Kidney Transplantation. <i>Transplantation</i> , 2012, 93, 822-826.	0.5	33
104	Challenges in Blood Pressure Measurement in Patients Treated With Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2012, 60, 463-472.	2.1	13
105	End-stage kidney disease due to haemolytic uraemic syndrome outcomes in 241 consecutive ANZDATA registry cases. <i>BMC Nephrology</i> , 2012, 13, 164.	0.8	7
106	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. <i>BMC Nephrology</i> , 2012, 13, 41.	0.8	27
107	Repeated Peritoneal Dialysis-associated Peritonitis: A Multicenter Registry Study. <i>American Journal of Kidney Diseases</i> , 2012, 59, 84-91.	2.1	19
108	Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. <i>Nephrology</i> , 2012, 17, 433-444.	0.7	42

#	ARTICLE	IF	CITATIONS
109	Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2011, 58, 1152-1161.	1.2	148
110	Frequent versus Standard Hemodialysis. New England Journal of Medicine, 2011, 364, 974-976.	13.9	7
111	Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?. Nephrology, 2011, 16, 144-153.	0.7	11
112	Relapsing and Recurrent Peritoneal Dialysis-Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2011, 58, 429-436.	2.1	63
113	Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology, 2011, 7, 295-300.	4.1	46
114	Effect of Dialysis Modality on Survival of Hepatitis C-Infected ESRF Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2657-2661.	2.2	6
115	Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2010, 25, 1973-1979.	0.4	84
116	Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2009, 2, 508-508.	1.4	8
117	Automated and continuous ambulatory peritoneal dialysis have similar outcomes. Kidney International, 2008, 73, 480-488.	2.6	68
118	Peritoneal Phosphate Clearance is Influenced by Peritoneal Dialysis Modality, Independent of Peritoneal Transport Characteristics. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1711-1717.	2.2	30
119	Phosphate Balance on Peritoneal Dialysis. Peritoneal Dialysis International, 2008, 28, 26-32.	1.1	13
120	Does Sevelamer reduce mortality by slowing of progression of coronary calcification?. Kidney International, 2007, 71, 1328-1329.	2.6	0
121	Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrology Dialysis Transplantation, 2006, 21, 776-783.	0.4	41
122	Case Report. Acute renal tubular injury with acute hepatitis A infection: Is it just a coincidence?. Nephrology, 2004, 9, 44-46.	0.7	10
123	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 0, , .	1.5	5
124	International Icodextrin Use and association with peritoneal membrane function, fluid removal, patient and technique survival. Kidney360, 0, , 10.34067/KID.0006922021.	0.9	4